(Q24243219)

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Azathioprine in Ulcerative Colitis: An Interim Report on a Controlled Therapeutic Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Safety of corticosteroids and immunosuppressive agents in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Review article: monitoring for drug side-effects in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

A national survey on the patterns of treatment of inflammatory bowel disease in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Tolerability of aminosalicylates in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Azathioprine for maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

7 January 2021

Immunosuppressive therapy for ulcerative colitis: results of a nation-wide survey among consultant physician members of the British Society of Gastroenterology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

7 January 2021

Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

7 January 2021

6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

7 January 2021

Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

7 January 2021

VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

7 January 2021

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000478.PUB2

7 January 2021